| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | 186.2% | Cantor Fitzgerald | $40 → $50 | Maintains | Overweight |
| 11/10/2023 | 43.1% | HC Wainwright & Co. | $17 → $25 | Maintains | Buy |
| 11/08/2023 | 60.27% | Morgan Stanley | $16 → $28 | Maintains | Overweight |
| 10/24/2023 | 128.96% | Cantor Fitzgerald | → $40 | Initiates Coverage On | → Overweight |
| 10/19/2023 | 77.45% | Stifel | → $31 | Initiates Coverage On | → Buy |
| 10/04/2023 | -2.69% | HC Wainwright & Co. | → $17 | Reiterates | Buy → Buy |
| 09/18/2023 | 123.24% | Wells Fargo | $14 → $39 | Maintains | Overweight |
| 09/05/2023 | 25.93% | Citigroup | → $22 | Initiates Coverage On | → Buy |
| 08/14/2023 | 94.62% | Guggenheim | → $34 | Reiterates | Buy → Buy |
| 08/11/2023 | -2.69% | HC Wainwright & Co. | $15 → $17 | Maintains | Buy |
| 07/18/2023 | 94.62% | Guggenheim | → $34 | Initiates Coverage On | → Buy |
| 05/17/2023 | -14.14% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/12/2023 | -14.14% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/03/2023 | -14.14% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 04/10/2023 | -14.14% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 04/03/2023 | -14.14% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 03/22/2023 | -31.31% | Chardan Capital | → $12 | Reiterates | → Buy |
| 03/17/2023 | -42.76% | Mizuho | → $10 | Reiterates | → Buy |
| 03/17/2023 | -14.14% | HC Wainwright & Co. | $11 → $15 | Maintains | Buy |
| 02/17/2023 | -37.03% | HC Wainwright & Co. | → $11 | Reiterates | → Buy |
| 01/27/2023 | -8.41% | Morgan Stanley | → $16 | Upgrades | Equal-Weight → Overweight |
| 01/03/2023 | -19.86% | Wells Fargo | $4 → $14 | Maintains | Overweight |
| 11/11/2022 | -31.31% | Chardan Capital | $13 → $12 | Maintains | Buy |
| 09/14/2022 | -77.1% | Wells Fargo | $14 → $4 | Maintains | Overweight |
| 08/30/2022 | -82.83% | Morgan Stanley | $15 → $3 | Downgrades | Overweight → Equal-Weight |
| 08/12/2022 | -25.59% | Chardan Capital | $17 → $13 | Maintains | Buy |
| 05/25/2022 | -42.76% | Mizuho | $20 → $10 | Maintains | Buy |
| 03/18/2022 | 14.48% | Mizuho | $22 → $20 | Maintains | Buy |
| 03/18/2022 | -37.03% | HC Wainwright & Co. | $22 → $11 | Maintains | Buy |
| 12/15/2021 | -14.14% | Morgan Stanley | $20 → $15 | Maintains | Overweight |
| 12/08/2021 | -2.69% | Wells Fargo | → $17 | Initiates Coverage On | → Overweight |
| 06/30/2021 | 25.93% | Mizuho | → $22 | Initiates Coverage On | → Buy |
| 03/17/2021 | 25.93% | HC Wainwright & Co. | $20 → $22 | Maintains | Buy |
| 01/08/2021 | 20.21% | Chardan Capital | → $21 | Initiates Coverage On | → Buy |
| 10/13/2020 | 14.48% | HC Wainwright & Co. | → $20 | Initiates Coverage On | → Buy |
| 07/15/2020 | 14.48% | Morgan Stanley | $19 → $20 | Maintains | Overweight |
| 11/19/2019 | 8.76% | Morgan Stanley | → $19 | Initiates Coverage On | → Overweight |
| 11/19/2019 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 11/19/2019 | 43.1% | Evercore ISI Group | → $25 | Initiates Coverage On | → Outperform |
What is the target price for Cabaletta Bio (CABA)?
The latest price target for Cabaletta Bio (NASDAQ: CABA) was reported by Cantor Fitzgerald on November 15, 2023. The analyst firm set a price target for $50.00 expecting CABA to rise to within 12 months (a possible 186.20% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cabaletta Bio (CABA)?
The latest analyst rating for Cabaletta Bio (NASDAQ: CABA) was provided by Cantor Fitzgerald, and Cabaletta Bio maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Cabaletta Bio (CABA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cabaletta Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cabaletta Bio was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
Is the Analyst Rating Cabaletta Bio (CABA) correct?
While ratings are subjective and will change, the latest Cabaletta Bio (CABA) rating was a maintained with a price target of $40.00 to $50.00. The current price Cabaletta Bio (CABA) is trading at is $17.47, which is out of the analyst's predicted range.